aTYR PHARMA INC 8-K

What Happened

• aTyr Pharma, Inc. (ATYR) reported preliminary, unaudited cash, cash equivalents, restricted cash and available-for-sale investments of approximately $68.3 million as of March 31, 2026 (Item 2.02).
• On May 11, 2026 the company announced receipt of official minutes from a Type C meeting with the FDA and released a corporate presentation (Item 7.01). Based on FDA feedback, aTyr plans to continue development of its lead candidate, efzofitimod, in pulmonary sarcoidosis with a new Phase 3 study; an IND for that study is planned for submission in June 2026 (Item 8.01).

Key Details

• New Phase 3 design: global, randomized, double-blind, placebo-controlled, 54-week study with two parallel cohorts; up to ~372 patients with symptomatic pulmonary sarcoidosis and restrictive lung disease (FVC % predicted ≤ 80%).
• Dosing: 5.0 mg/kg efzofitimod or placebo intravenously once every 3 weeks for 17 doses (increased from once every 4 weeks in prior trials). FDA found this dosing frequency reasonable with adequate safety monitoring.
• Endpoints: primary endpoint is change from baseline in forced vital capacity (FVC) at Week 48; key secondary endpoint is change from baseline in King's Sarcoidosis Questionnaire (KSQ)-Lung score at Week 48.
• Safety and oversight: company plans enhanced safety surveillance for anti-synthetase syndrome, additional risk mitigation strategies, and a data safety monitoring committee.

Why It Matters

• The filing shows aTyr is moving forward with efzofitimod development after FDA feedback, defining a clearer Phase 3 path (population, endpoints, dosing) and targeting an IND submission in June 2026—important milestones for clinical and regulatory progress.
• The specified primary endpoint (FVC) and focus on patients with restrictive lung disease narrow the trial population and set measurable outcomes that the FDA considers direct measures of how patients function and feel.
• The company’s reported ~$68.3M cash position is preliminary and unaudited; the filing warns actual results may differ and includes standard forward-looking statement disclosures about risks, timelines and funding needs.